Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma vaccines.

D Schadendorf1

  • 1Clinical Cooperation Unit for Dermatooncology (DKFZ), Department of Dermatology, Clinics Mannheim, University of Heidelberg, Mannheim, Germany.

Drug News & Perspectives
|August 26, 2003
PubMed
Summary

Immunotherapies for melanoma harness the immune system, using gene-modified tumor cells and peptide vaccines. Clinical trials show these melanoma treatments are promising, with dendritic cell vaccines being safe and effective.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Melanoma treatment research is exploring immunotherapies to leverage the host's immune system.
  • Current strategies aim to enhance tumor cell immunogenicity and utilize melanoma-associated peptides.

Purpose of the Study:

  • To review and summarize current immunotherapeutic approaches for melanoma treatment.
  • To highlight the progress and potential of gene-modified tumor vaccines and peptide-based vaccines.

Main Methods:

  • Gene modification of tumor cells with cytokine genes (e.g., IL-7, IL-12, GM-CSF, interferon gamma).
  • Development and application of T cell-defined melanoma-associated peptide vaccines.
  • Generation and use of autologous dendritic cell-based vaccines.

Main Results:

  • Preclinical studies established principles for cytokine gene-modified tumor vaccines, leading to phase I/II trials.
  • Clinical studies indicate peptide immunization is a potentially effective melanoma treatment.
  • Vaccination with autologous dendritic cells shows safety and promise.

Conclusions:

  • Immunotherapeutic strategies, including cytokine gene-modified vaccines and peptide vaccines, show encouraging results for melanoma treatment.
  • Dendritic cell-based vaccines represent a safe and promising approach.
  • Further clinical studies with larger patient cohorts are warranted to confirm efficacy.

Related Experiment Videos